You're shaking your head.

Sure, I've spent too much time on alpha-gal syndrome in three years, so I do know this a little bit better than most.

So there are still many questions about alpha-gal syndrome and how it works in the body and who gets it and who doesn't.

There are plenty of people who get lone star tick bites and do not develop the allergy.

So why that's happening and why other people are developing the allergy is still an active part of science.

But basically what's happening is there's a molecule in a lone star tick bite that looks like a molecule called galactose alpha-1,3-galactose.

That's a mouthful.

So what's going on there? Is it just a lot of medical people aren't familiar with it to give that test?

But that's the sense of where those samples came from and how they were selected.

And it's a fascinating study and very helpful because this background positivity rate, regardless of symptoms, helps us understand when we do the public health surveillance.

We get those positive reports and we actually follow up with those patients to figure out, do you have symptoms or do you not? And so basically we then have a denominator.

That's what your seroprevalence data is, is a denominator.

How many people test positive? versus how many people are truly symptomatic.

And that's what the public health case investigation work is really trying to do.

And so it'll be very interesting to see and compare that seroprevalence data from those states to what they're going to do if they have alpha-gal reportability in those states, kind of how that works out.

Are there... um aerial interventions that does it all have to be on the ground